Reviva Free Cash Flow Yield from 2010 to 2024
| RVPH Stock | USD 2.61 0.16 5.78% |
Free Cash Flow Yield | First Reported 2010-12-31 | Previous Quarter (0.23) | Current Value (0.24) | Quarterly Volatility 0.1053224 |
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 156.3 K, Tax Provision of 10 K or Net Interest Income of 523.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.5. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
Reviva | Free Cash Flow Yield |
Latest Reviva Pharmaceuticals' Free Cash Flow Yield Growth Pattern
Below is the plot of the Free Cash Flow Yield of Reviva Pharmaceuticals Holdings over the last few years. It is a financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share. Reviva Pharmaceuticals' Free Cash Flow Yield historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Free Cash Flow Yield | 10 Years Trend |
|
Free Cash Flow Yield |
| Timeline |
Reviva Free Cash Flow Yield Regression Statistics
| Arithmetic Mean | (0.08) | |
| Coefficient Of Variation | (135.82) | |
| Mean Deviation | 0.09 | |
| Median | (0.01) | |
| Standard Deviation | 0.11 | |
| Sample Variance | 0.01 | |
| Range | 0.2421 | |
| R-Value | (0.82) | |
| Mean Square Error | 0 | |
| R-Squared | 0.68 | |
| Significance | 0.0002 | |
| Slope | (0.02) | |
| Total Sum of Squares | 0.16 |
Reviva Free Cash Flow Yield History
About Reviva Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Reviva Pharmaceuticals' Free Cash Flow Yield, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Free Cash Flow Yield | (0.23) | (0.24) |
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out the analysis of Reviva Pharmaceuticals Correlation against competitors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.